Enter your terms above and click the 'Search' button.

Showing articles 0 to 12 of 12 Filter Applied: immune checkpoint inhibitors (Click to remove) Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum Ann Neurol 87:659-669, Dubey, D.,et al, 2020 Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma Neurol 94:322-323, Zaloum, A.,et al, 2020 Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum Ann Neurol 87:659-669, Dubey, D.,et al, 2020 Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies Neurol 92:663-674, Johansen, A.,et al, 2019 Acute demyelinating polyneuropathy induced by nivolumab JNNP 89:435-437, Fukumoto, Y.,et al, 2018 Pembrolizumab-Induced Myasthenia Gravis Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018 Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016 Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors in Patients with Melanoma Neurol 101:e2472-e2482, Pepys,J.,et al, 2023 Encephalitis Induced by Immune Checkpoint Inhibitors JAMA Neurol 78:864-873, Velasco, R.,et al, 2021 Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors Neurol 97:e191-e202, Nersesjan, V.,et al, 2021 Association of Innovations in Radiotherapy and Systemic Treatments with Clinical Outcomes in Patients with Melanoma Brain Metastasis From 2007 to 2016 JAMA doi:10.1001/JAMANETWORKOPEN.2020.8204, Brastianos, H.C.,et al, 2020 Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer Neurol 91:e985-e994, Touat, M.,et al, 2018 Showing articles 0 to 12 of 12